Skip to main content
Breadcrumb
Home
Publications
Publications
Adelakun A, Dolph M, Matthews E, Oglebsy A, Campbell K , Davis A , Xu J, Hardy I, Danchenko N, Anderson SJ. Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada . Poster presented at the HIV Drug Therapy Glasgow 2024; November 10, 2024. Glasgow, Scotland. [abstract] J Int AIDS Soc. 2024 Nov; 27:234-5.
Niyazov A, Simou E , Kirker M, Houghton K , Le Moine JG , Chang J, Yarr S , Barnett C , Mladsi D . Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations . Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772
Niyazov A, Simou E , Kirker M, Houghton K , Le Moine JG , Chang J, Yarr S , Barnett C , Mladsi D . Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations . Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S119. doi: 10.1016/j.jval.2023.09.772
Morris MJ, Armstrong AJ, Chi K, de Bono J, Herrmann K, Krause B, Rahbar K, Sartor O, Tagawa ST, Nagarajah J, Wei XX, Nordquist LT, Koshkin VS, Saad F, Vickers A , Ghouse R, Wu J, Mirante O, Fizazi K. Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer . Poster presented at the ESMO Congress 2023; October 22, 2023. Madrid, Spain.
Njue A , Margulis AV , Lyall M, Nuabor W , Marks M, Russell K, Sinha A. Congenital cytomegalovirus: what are the rates of maternal screening, diagnostic amniocentesis, and elective termination? Poster presented at the ID Week 2019; October 4, 2019. Washington, DC.